Sanctuary Advisors’s AbCellera Biologics ABCL Stock Holding History

Sanctuary Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,359	Closed	-$35.5K	–	2414
2025 Q2	$35.5K	Sell	10,359 -45,373	-81%	-$113K	﹤0.01%	2324
2025 Q1	$124K	Sell	55,732 -33,884	-38%	-$97.2K	﹤0.01%	2091
2024 Q4	$289K	Sell	89,616 -5,500	-6%	-$15.3K	﹤0.01%	2019
2024 Q3	$263K	Sell	95,116 -10,808	-10%	-$29.9K	﹤0.01%	2081
2024 Q2	$398K	Buy	+105,924	New	+$401K	﹤0.01%	1789

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Sanctuary Advisors's ABCL Position: Q3 2025 in Review

Sanctuary Advisors sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 10,359 shares — an estimated $35.5K sold.

Sanctuary Advisors first reported a position in ABCL in Q2 2024 and held it in 5 quarters. The position peaked at $398K in Q2 2024. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

Sanctuary Advisors reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
Sanctuary Advisors sold 10,359 AbCellera Biologics shares in Q3 2025, an estimated $35.5K.
Sanctuary Advisors first reported a position in AbCellera Biologics in Q2 2024 and held it in 5 quarters.
Sanctuary Advisors's AbCellera Biologics position peaked at $398K in Q2 2024.
141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Sanctuary Advisors's 13F filing for Q3 2025, filed 6 Jan 2026.